Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5079643 | 1.00 | SLC7A5 (0.43) | SLC7A5GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL4412222 | 0.81 | SLC1A1 (0.50) | GRIK1GRIK2GRM1GRM2SLC1A3 | |
| SCHEMBL402417 | 0.79 | GRIK1 (0.47) | SLC7A5GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL1512966 | 0.79 | GRIK1 (0.47) | SLC7A5GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL10557340 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL10545518 | 0.77 | CTSC (0.34) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL359953 | 0.77 | SLC1A1 (0.45) | SLC7A5GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL5082612 | 0.76 | SLC7A5 (0.54) | SLC7A5GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL5082599 | 0.76 | SLC7A5 (0.54) | SLC7A5GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL2807629 | 0.75 | PTGS1 (0.45) | SLC7A5GRIK1GRIK2GRM1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562564-A2 | COMBINATION CANCER THERAPY WITH A GST-ACTIVATED ANTICANCER COMPOUND AND ANOTHER ANTICANCER THERAPY | TELIK, INC. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040138140-A1 | Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy | TELIK, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004045593-A2 | COMBINATION CANCER THERAPY WITH A GST-ACTIVATED ANTICANCER COMPOUND AND ANOTHER ANTICANCER THERAPY | TELIK, INC. (US) | 2004-06-03 | — | — | WO | claimed |
| US-20080159980-A1 | Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy | TELIK, INC. | 2008-07-03 | — | — | US | disclosed |
| EP-1562564-A2 | COMBINATION CANCER THERAPY WITH A GST-ACTIVATED ANTICANCER COMPOUND AND ANOTHER ANTICANCER THERAPY | TELIK, INC. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040138140-A1 | Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy | TELIK, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004045593-A2 | COMBINATION CANCER THERAPY WITH A GST-ACTIVATED ANTICANCER COMPOUND AND ANOTHER ANTICANCER THERAPY | TELIK, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-0254735-B2 | METHOD FOR PRODUCTION OF THERMALLY STABLE AND pH STABLE SUBTILISIN ANALOGS | AMGEN INC (US) | 1998-06-17 | — | — | EP | disclosed |
| US-5399283-A | Asparagine in polypeptide sequence is replaced; detergents | AMGEN INC. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0254735-B1 | THERMALLY STABLE AND PH STABLE SUBTILISIN ANALOGS AND METHOD FOR PRODUCTION THEREOF | AMGEN INC. (US) | 1991-06-19 | — | — | EP | disclosed |
| EP-0254735-A1 | THERMALLY STABLE AND pH STABLE SUBTILISIN ANALOGS AND METHOD FOR PRODUCTION THEREOF. | AMGEN (US) | 1988-02-03 | — | — | EP | disclosed |
| EP-0254735-A4 | THERMALLY STABLE AND pH STABLE SUBTILISIN ANALOGS AND METHOD FOR PRODUCTION THEREOF. | AMGEN (US) | 1988-01-07 | — | — | EP | disclosed |
| WO-1987004461-A1 | THERMALLY STABLE AND pH STABLE SUBTILISIN ANALOGS AND METHOD FOR PRODUCTION THEREOF | AMGEN (US) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080159980-A1 | Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy | GSTK1, GSTA2, GSTA1 | SLC7A5 975/4885GRIK1 1363/4885GRIK2 1674/4885 |
| US-20040138140-A1 | Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy | GSTK1, GSTA2, GSTA1 | SLC7A5 933/4885GRIK1 1353/4885GRIK2 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.